Acute Myeloid Leukemia Clinical Trial
Official title:
Telomere and Telomerase
Researchers hope to determine if the DNA is shortened in your body and determine if there is an increase in the protein that shortens DNA called telomerase.
A telomere is a region of repetitive DNA at the end of chromosomes, which protects the end
of the chromosome from destruction. Telomeres can be viewed as the tips on the ends of
shoelaces that keep them from unraveling. Telomeres compensate for incomplete
semi-conservative DNA replication at chromosomal ends. In absence of a reparative process,
DNA sequences would be lost in every replicative phase until they reached a critical level,
at which point cell division would stop.
Loss of telomeres leads to chromosome end-to-end fusion, chromosome re-arrangements, and
genome instability.
Telomerase is a "ribonucleoprotein complex" composed of a protein component and an RNA
primer sequence which acts to protect the terminal ends of chromosomes. Telomerase is the
natural enzyme which promotes telomere repair. It is however not active in most cells. It
certainly is active though in stem cells, germ cells, hair follicles and in 90 percent of
cancer cells. Telomerase functions by adding bases to the ends of the telomeres. As a result
of this telomerase activity, these cells seem to possess a kind of immortality.
Progressive shortening or attrition of telomere length with consequent genomic instability
leading to cancer has been described in various hematological malignancies including acute
and chronic myeloid leukemia.
Reduced telomere length has been documented in patients with the progressive BM failure
syndrome called Dyskeratosis Congenita. Abnormalities in these patients include skin
pigmentation, nail dystrophy and leukoplakia. Mutations in the telomere maintenance
mechanism have been implicated in the pathogenesis of this heterogeneous condition.
Myelodysplastic syndrome is an acquired clonal stem cell disorder characterized by
in-effective hematopoiesis, increased intra-medullary apoptosis and peripheral cytopenia. A
number of such patients will eventually develop worsening cytopenia evolving into acute
myeloid leukemia. A number of studies have investigated telomerase activity and telomere
length in patients with MDS and AML. Telomere shortening was significantly more pronounced
in patients with cytogenetic alterations as compared to patients with normal karyotypes.
Genomic instability develops with progressive telomere shortening. The Telomere attrition
related genome instability is a stress that leads to up-regulation of specified DNA damage
foci. These telomere-associated DNA damage points are often called as Telomere
Dysfunction-Induced Focus (TIF).
;
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |